A recent phase II clinical study compared combination of pyrotinib with capecitabine17,141–143 and lapatinib with capecitabine, to treat the patients with advanced HER2-positive breast cancer who had previously used/not used trastuzumab within two lines. The gene discussed is ERBB2; the disease is breast cancer.